BioCentury
ARTICLE | Clinical News

ATX-MS-1467: Completed Phase IIa enrollment

September 14, 2015 7:00 AM UTC

Merck completed enrollment in an open-label, German Phase IIa trial evaluating ATX-MS-1467 for 20 weeks. Patients’ ATX-MS-1467 doses are titrated during the first 4 weeks of treatment. Merck has exclu...